Literature DB >> 8388434

AIDS dementia complex complicated by cytomegalovirus encephalopathy.

M Fiala1, E J Singer, M C Graves, W W Tourtellotte, J A Stewart, C A Schable, R H Rhodes, H V Vinters.   

Abstract

We have studied longitudinally ten patients with AIDS encephalopathy with respect to pathogenetic roles of human immunodeficiency virus (HIV) and cytomegalovirus (CMV). Three patients manifested typical AIDS dementia complex (ADC) (initially without retinitis and with slowly progressive cognitive, motor and behavioral abnormalities which were zidovudine-responsive, and relatively preserved CD4+ T cells), and seven patients presented with AIDS dementia complex complicated by CMV encephalopathy (ACE) (with CMV retinitis, peripheral neuropathy, altered sensorium, and rapidly declining clinical and immunological status). Whereas only HIV antibody was elevated in the spinal fluid of patients with ADC, both virus infections were active in the central nervous system of patients with ACE as shown by HIV p24 antigenemia and antigenrrhachia, elevated HIV and CMV antibody in the spinal fluid, disseminated CMV infection with retinitis, and basilar ventriculoencephalitis with multinucleated cytomegalic cells containing CMV and HIV proteins and CMV DNA. The recognition of ADC and ACE is important, since some patients with ACE may respond to ganciclovir or foscarnet.

Entities:  

Mesh:

Year:  1993        PMID: 8388434     DOI: 10.1007/bf00818709

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  41 in total

Review 1.  AIDS meningoencephalomyelitis. Pathogenesis and changing neuropathologic findings.

Authors:  R H Rhodes; J M Ward
Journal:  Pathol Annu       Date:  1991

2.  Persistent productive infection of human glial cells by human immunodeficiency virus (HIV) and by infectious molecular clones of HIV.

Authors:  S Dewhurst; K Sakai; J Bresser; M Stevenson; M J Evinger-Hodges; D J Volsky
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

3.  Immunohistochemical identification of HTLV-III antigen in brains of patients with AIDS.

Authors:  D H Gabuzda; D D Ho; S M de la Monte; M S Hirsch; T R Rota; R A Sobel
Journal:  Ann Neurol       Date:  1986-09       Impact factor: 10.422

4.  Cytomegalovirus viremia increases with progressive immune deficiency in patients infected with HTLV-III.

Authors:  M Fiala; L A Cone; C M Chang; E S Mocarski
Journal:  AIDS Res       Date:  1986

5.  Role of human immunodeficiency virus and cytomegalovirus in AIDS encephalitis.

Authors:  C A Wiley; J A Nelson
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

6.  Human immunodeficiency virus (HIV) infection in brains with AIDS-related leukoencephalopathy.

Authors:  S W Rostad; S M Sumi; C M Shaw; K Olson; J K McDougall
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

7.  Cytotoxic factors secreted by cells infected by human immunodeficiency virus type I.

Authors:  L Ratner; S H Polmar; N Paul; N Ruddle
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

8.  Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus.

Authors:  P R Skolnik; B R Kosloff; M S Hirsch
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

9.  Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome.

Authors:  D D Ho; T R Rota; R T Schooley; J C Kaplan; J D Allan; J E Groopman; L Resnick; D Felsenstein; C A Andrews; M S Hirsch
Journal:  N Engl J Med       Date:  1985-12-12       Impact factor: 91.245

10.  Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome.

Authors:  M P Heyes; D Rubinow; C Lane; S P Markey
Journal:  Ann Neurol       Date:  1989-08       Impact factor: 10.422

View more
  9 in total

1.  Cytomegalovirus cell tropism, replication, and gene transfer in brain.

Authors:  A N van Den Pol; E Mocarski; N Saederup; J Vieira; T J Meier
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

2.  Evaluation of a commercial PCR kit for diagnosis of cytomegalovirus infection of the central nervous system.

Authors:  A Weinberg; D Spiers; G Y Cai; C M Long; R Sun; V Tevere
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

3.  TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier.

Authors:  M Fiala; D J Looney; M Stins; D D Way; L Zhang; X Gan; F Chiappelli; E S Schweitzer; P Shapshak; M Weinand; M C Graves; M Witte; K S Kim
Journal:  Mol Med       Date:  1997-08       Impact factor: 6.354

4.  Relevance of clinical and laboratory findings in the diagnosis of cytomegalovirus encephalitis in patients with AIDS.

Authors:  C Mussini; N Mongiardo; G Manicardi; F Trenti; A Alessandrì; F Paolillo; A Catania; M Portolani; M Pecorari; V Borghi; G Ficarra; A Cossarizza; B De Rienzo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-06       Impact factor: 3.267

Review 5.  Neurologic presentations of AIDS.

Authors:  Elyse J Singer; Miguel Valdes-Sueiras; Deborah Commins; Andrew Levine
Journal:  Neurol Clin       Date:  2010-02       Impact factor: 3.806

6.  Long-distance interferon signaling within the brain blocks virus spread.

Authors:  Anthony N van den Pol; Siyuan Ding; Michael D Robek
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

7.  Cytomegalovirus infection of the brain in AIDS: a clinicopathological study.

Authors:  U Setinek; E Wondrusch; K Jellinger; A Steuer; M Drlicek; W Grisold; F Lintner
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

8.  Ectopic expression of gamma interferon in the eye protects transgenic mice from intraocular herpes simplex virus type 1 infections.

Authors:  K Geiger; E L Howes; N Sarvetnick
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

Review 9.  Long-term neuropsychological deficits after central nervous system infections despite adequate therapy.

Authors:  Roland Nau; Holger Schmidt
Journal:  J Neurol       Date:  2007-05       Impact factor: 6.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.